AstraZeneca and Peregrine are expanding their ongoing onco-immunotherapy pact to allow for a Phase II trial of an experimental lung cancer combination treatment.
The companies said they will test a combination of Peregrine’s phosphatidylserine-targeted immune-activator bavituximab and AZ’ anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer.
{iframe}http://www.pharmatimes.com/Article/15-10-15/AZ_Peregrine_expand_cancer_immunotherapy_pact.aspx{/iframe}